Non‑Cystic Fibrosis Bronchiectasis Market to Witness Robust Growth by 2035 – BIS Research

What is non‑cystic fibrosis bronchiectasis? 

Non‑cystic fibrosis bronchiectasis is a chronic respiratory condition marked by irreversible dilation of the airways, leading to recurrent infections, persistent cough, sputum production, and declining lung function. It is distinct from cystic fibrosis–related bronchiectasis and affects hundreds of thousands globally, with an estimated 350,000–500,000 U.S. cases. 

What Is the Market Outlook? 

Hospitals, pulmonary clinics, and ambulatory care centers are expanding focus on earlier detection using CT scans, lung function tests, and sputum cultures. This diagnostic evolution, paired with novel drug development (e.g., antibiotics, bronchodilators, corticosteroids, biologics), fosters steady demand. Pharmaceutical competition is intense, with companies racing to advance pipeline drugs, especially after late-stage trial successes like brensocatib. 

How Fast Is the Market Growing? 

The non‑cystic fibrosis bronchiectasis (NCFB) market is projected to grow steadily over the forecast period. While growth estimates vary across research sources, all projections point to a strong upward trajectory. This momentum is largely fueled by advancements in biologic therapies, increased disease awareness, expanding diagnostic capabilities, and the rising demand for targeted treatments. Overall, the market reflects significant untapped potential and increasing commercial interest. 

How Will This Report Help You? 

Planning to Enter the Market? 

Understand regional diagnostic adoption and treatment utilization across North America, Europe, Asia‑Pacific, Latin America, Middle East & Africa. Focus on segments like antibiotics, bronchodilators, corticosteroids, and biologics such as DPP‑1 inhibitors. 

Analyzing the Competitive Landscape? 

Benchmark leading pharma firms (AstraZeneca, Sanofi, Insmed, Boehringer‑Ingelheim, Zambon, Chiesi, Haisco, Regeneron, etc.) across drug classes, late‑stage assets, regulatory filings, and clinical trial milestones. 

Seeking R&D Insights? 

Gain visibility into innovative therapies—late-stage biologics (e.g., brensocatib), targeted antibiotics, inhaled anti-inflammatories, and novel diagnostics like CT and lung function integration. 

Interested in Regional Market Trends? 

Explore segmented data: by treatment, diagnostics type, end‑use (hospitals, ambulatory), country-level CAGR; forthcoming uptake patterns for China, U.S., Europe. 

Download the Full TOC and Report Sample   

What Technologies Are Transforming the Market? 

• Novel biologic therapies targeting inflammatory pathways (e.g., brensocatib, DPP‑1 inhibitors)  
• Advanced diagnostics: HRCT, lung function tests, sputum culture, blood biomarkers 
• Inhalable antibiotics, corticosteroids, bronchodilators with improved delivery systems. 

Unlock Critical Insights with Surgical Procedure Database 

Discover BIS Research Surgical Procedure Volume Database – your key to real-world, country-level procedural insights across MedTech. 

What’s Driving Demand, Opportunity and Barriers?

Drivers: 

• Growing diagnosed patient population via improved imaging and awareness 
• Clinical momentum behind targeted therapies, including biologics 
• Demand for chronic care and prevention of exacerbations. 

Barriers: 

• Market fragmentation and inconsistent reimbursement 
• High treatment costs, especially for biologics 
• Limited access in lower‑income regions; insufficient hospital infrastructure. 

Opportunities: 

• Rapid uptake of FDA‑approved biologics post-brensocatib filing expected Q4 2024 Public-private initiatives for screening using CT scans 
• Expansion of care in ambulatory and outpatient settings. 

How Is the Market Segmented? 

by Drug Class 

•    Antibiotics 

•    Corticosteroids 

•    Bronchodilators 

•    Others 

by Region 

•    North America 

•    Europe  

•    Asia-Pacific 

Download the complete TOC now! 

Strategic Moves Shaping the Future: 

• Accelerated FDA filing and commercialization of brensocatib (~mid‑2025 U.S., early 2026 EU/Japan)  
• R&D emphasis on biologic anti-inflammatories and improved antibiotic inhalation therapies 
• Enhanced diagnostic networks: CT imaging deployment and sputum test standardization. 

Case Study: Brensocatib by Insmed 

Insmed’s brensocatib a selective DPP‑1 inhibitor showed 19–21 % reduction in annualized pulmonary exacerbations in a 1,680‑patient Phase III trial, with good safety profile. Its success triggered a ~100–119 % stock surge, and Insmed plans FDA submission in Q4 2024 with U.S. launch mid‑2025 and EU/Japan launches in 2026. Peak sales are forecast at USD 4.5–8 billion by 2033. 

Schedule a Call with Industry Experts  

Related Reports from BIS Research  

Coagulation Factor Deficiency Market 

Hyperopia Market 

Behcet’s Disease Market 

About BIS Research  

BIS Research is a global B2B market intelligence and advisory firm focusing on deep technology and related emerging trends, which can disrupt the market dynamics in the near future. We publish over 200 market intelligence studies annually, focusing on several deep technology verticals.    

Our strategic market analysis emphasizes market estimations, technology analysis, emerging high-growth applications, deeply segmented granular country-level market data, and other important market parameters useful in the strategic decision-making for senior management.     

BIS Research offers syndicate and custom studies and expert consultations to firms, providing them with specific and actionable insights on novel technology markets, business models, and competitive landscapes.    

Contact  

Head of Marketing   

Email: media@bisresearch.com     

BIS Research Inc.    

39111 PASEO PADRE PKWY STE 313,    

FREMONT, CA 94538-1686   

Visit our Blog @https://bisresearch.com/insights    

Get Expert Insights @https://community.insightmonk.com     

Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research     

Connect with us on Twitter@ https://twitter.com/BISResearch    

Connect with us on Medium@ https://medium.com/@faisal.bis  

Connect with us on YouTube@ https://www.youtube.com/@BISResearchInc